Acacia Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...7891011121314151617...2223»
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Initial Experiences With Remimazolam For Pediatric Procedural Sedation: A Case Series Study (Exhibit Hall) -  Jul 20, 2023 - Abstract #ASA2023ASA_487;    
    In conclusion, remimazolam demonstrated both safety and efficacy in pediatric procedural sedation, with hemodynamic variability that did not necessitate pharmacologic intervention. Our initial case series supports its potential application in the pediatric population and highlights the importance of further large-scale studies for optimizing dosing, efficacy, and safety.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Effect of Remimazolam vs. Desflurane Anesthesia on Arterial Oxygenation During One-Lung Ventilation. (South: Hall F) -  Jul 20, 2023 - Abstract #ASA2023ASA_269;    
    Inhaled anesthetics such as desflurane have been suggested to inhibit HPV, while intravenous anesthetics such as propofol and ketamine have no effect on HPV. The rate of the lowest PaO2 during OLV to PaO2 during TLV in remimazolam-remifentanil anesthesia was higher than that in desflurane-remifentanil anesthesia for thoracoscopic surgery, indicating remimazolam is less impact on PaO2 during OLV than desflurane.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Remimazolam Total Intravenous Anesthesia Under Analgesia Nociception Index-guidance (clinicaltrials.gov) -  Jul 20, 2023   
    P=N/A,  N=84, Completed, 
    The rate of the lowest PaO2 during OLV to PaO2 during TLV in remimazolam-remifentanil anesthesia was higher than that in desflurane-remifentanil anesthesia for thoracoscopic surgery, indicating remimazolam is less impact on PaO2 during OLV than desflurane. Recruiting --> Completed | Trial completion date: Mar 2024 --> Jul 2023 | Trial primary completion date: Mar 2024 --> Jul 2023
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Surgery:  Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam (clinicaltrials.gov) -  Jul 20, 2023   
    P=N/A,  N=73, Completed, 
    Recruiting --> Completed | Trial completion date: Mar 2024 --> Jul 2023 | Trial primary completion date: Mar 2024 --> Jul 2023 Recruiting --> Completed
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Trial completion date:  A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients (clinicaltrials.gov) -  Jul 14, 2023   
    P=N/A,  N=120, Completed, 
    This approach represents an alternative method for patients with circulatory risk undergoing femoral surgery. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2023
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion date, Trial primary completion date, Surgery:  Comparison of Postoperative QoR-15 Scores Between Desflurane and Remimazolam in Lumbar Fusion Surgery (clinicaltrials.gov) -  Jul 3, 2023   
    P=N/A,  N=76, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2023 Trial completion date: Jul 2023 --> Jun 2024 | Trial primary completion date: Jul 2023 --> Jun 2024
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Enrollment open:  Effect of Sevoflurane and Remimazolam on Arterial Oxygenation During One-lung Ventilation (clinicaltrials.gov) -  Jul 3, 2023   
    P=N/A,  N=58, Recruiting, 
    Trial completion date: Jul 2023 --> Jun 2024 | Trial primary completion date: Jul 2023 --> Jun 2024 Not yet recruiting --> Recruiting
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Anesthetic Management Using Remimazolam in a Hemodialysis Patient. (Pubmed Central) -  Jul 2, 2023   
    Hemodynamic control was stable during the anesthetic, which was safely completed without any adverse events and resulted in a rapid, clear emergence without flumazenil. Remimazolam and remifentanil may be appropriate as first-line general anesthetic agents for hemodialysis patients with heart failure.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Review, Journal:  A Narrative Review of Remimazolam in Procedural Sedation. (Pubmed Central) -  Jun 30, 2023   
    Remimazolam has a mild cardiopulmonary suppressive effect, showing good effectiveness and safety in clinical applications, especially in the elderly, critically ill patients, or patients with hepatic and renal insufficiency. This review aims to provide an overview of the specific basic and clinical pharmacology of remimazolam and provide scientific support for the clinical application of this novel sedative drug in procedural sedation.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Enrollment status:  The Effect of Remimazolam on Opioid Induced Hyperalgesia (clinicaltrials.gov) -  Jun 27, 2023   
    P=N/A,  N=108, Enrolling by invitation, 
    The risk of hemodynamic variability which necessitates and responds to ephedrine should be anticipated. Recruiting --> Enrolling by invitation
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients (clinicaltrials.gov) -  Jun 22, 2023   
    P=N/A,  N=122, Active, not recruiting, 
    A combination of remimazolam and propofol was recommended to produce stabler sedation, reduce the total dosage and have less effect on cardiovascular and respiratory depression. Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Dec 2022
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Journal, Surgery:  Comparison of bispectral index and patient state index as measures of sedation depth during surgeries using remimazolam tosilate. (Pubmed Central) -  Jun 20, 2023   
    According to correlation analyses with MOAA/S scale and ROC curves, BIS is more accurate than PSI during such intraoperative monitoring. In addition, RT can be safely used in elderly patients under intraspinal anesthesia for supportive sedation, with stable vital signs and sound kidney and liver safety profiles.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Acacia Pharma
    Journal:  Remimazolam: a new reminder to keep our guard up. (Pubmed Central) -  Jun 9, 2023   
    This case suggests that remimazolam is one of the options for anesthetic management in PEA. No abstract available
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Acacia Pharma
    Review, Journal, Surgery:  The Role of Remimazolam in Neurosurgery and in Patients With Neurological Diseases: A Narrative Review. (Pubmed Central) -  Jun 2, 2023   
    In addition, the impact of remimazolam on postoperative excitation, risk for postoperative delirium, and delayed neurocognitive recovery are discussed. Although there seems to be a clinical promise for remimazolam based on limited case studies and our own institutional experience of its use, further clinical investigation is warranted to understand the potential impact of remimazolam on surgical and neurological outcomes.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Acacia Pharma
    Journal:  Remimazolam: a new string to the TIVA bow. (Pubmed Central) -  Jun 1, 2023   
    Although there seems to be a clinical promise for remimazolam based on limited case studies and our own institutional experience of its use, further clinical investigation is warranted to understand the potential impact of remimazolam on surgical and neurological outcomes. No abstract available
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Enrollment open:  LoSReB: Long-term Sedation With Remimazolam Besylate in Critically Ill Patients (clinicaltrials.gov) -  May 26, 2023   
    P3,  N=728, Recruiting, 
    However, stable hemodynamics with RMMZ were not sufficient to influence the prevention of AKI. Not yet recruiting --> Recruiting
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients (clinicaltrials.gov) -  May 24, 2023   
    P4,  N=552, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Oct 2022 --> Dec 2022
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    New trial:  The Effect of Remimazolam on Opioid Induced Hyperalgesia (clinicaltrials.gov) -  May 19, 2023   
    P=N/A,  N=108, Recruiting, 
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Surgery:  Reversal of Remimazolam by a Single Dose of Flumazenil (clinicaltrials.gov) -  May 19, 2023   
    P=N/A,  N=224, Completed, 
    NCT05350085. Recruiting --> Completed
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Surgery:  Comparison of IONM Between Remimazolam and Propofol (clinicaltrials.gov) -  May 18, 2023   
    P=N/A,  N=66, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Enrollment open, Trial completion date, Trial primary completion date, Surgery:  Remimazolam and Propofol on the Left Ventricular Strain During Anesthesia Induction for Non-cardiac Surgery (clinicaltrials.gov) -  May 9, 2023   
    P4,  N=40, Recruiting, 
    We found that procedural sedation with remimazolam was associated with economically meaningful savings compared to procedural sedation with midazolam and propofol in colonoscopies and to midazolam in bronchoscopies. Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Nov 2023
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial primary completion date:  Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia (clinicaltrials.gov) -  May 8, 2023   
    P4,  N=102, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Nov 2023 Trial primary completion date: Aug 2022 --> Aug 2023